- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A GP complained that a Toviaz ad also promoted tolterodine without required prescribing information. The Panel ruled a breach of Clause 4.1,…
A journal-lookalike insert reporting a “UK Psychiatry Forum” was ruled disguised promotion because it was output from a company-run promotional symposium and…
The MHRA complained that a Zoladex journal advertisement referenced the MHRA. The Panel ruled this breached Clause 9.5 because the MHRA had…
A GP alleged a calcium/vitamin D service lacked proper practice authorisation and involved patient letters and promotion of Adcal-D3. The Panel found…
Anonymous complaint questioned GSK’s POINTS COPD audit service as a potential rep monitoring/inducement tool. Panel found clear separation of promotional/non-promotional roles and…
Pfizer’s Toviaz ad claimed superiority vs tolterodine based on a post hoc analysis and called Toviaz “a new step” in OAB. The…
Boehringer Ingelheim admitted a rep emailed an orthopaedic surgeon claiming rivaroxaban was removed from a formulary due to bleeding concerns. PMCPA found…
Bracco sent 3,221 UK radiology HCPs a letter summarising a US legal case vs GE Healthcare. The PMCPA ruled the summary was…
Allergan’s Botox materials referenced “20 licensed indications worldwide” and used the headline “A BIG difference”. PMCPA ruled the worldwide indications framing and…
PMCPA case summary for AUTH/2198/10/9 (Primary Care Trust v Solvay). The provided case text contains no details on allegations, outcome, clauses, or…
A “Dear Pharmacist” tender letter claimed the NPSA “recommends” only licensed ready-to-use injectables. PMCPA said the NPSA expressed a preference and the…
A UK speaker meeting complaint found Daiichi-Sankyo reimbursed a US speaker for drinks likely consumed by accompanying family members. Breach of hospitality…
Sandoz’s German-issued press release referencing NICE guidance was held to be within the UK Code. One statement implying NICE found “no differences”…
Pfizer’s 5‑year budget impact model and ad promoted Xalatan/Xalacom using speculative post‑patent savings and referenced a paediatric programme inconsistent with the SPC.…
Otsuka Europe admitted potential Code issues after confusing affiliate communications on parallel Jinarc SPC variations and an out-of-date package leaflet being packed.…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.